Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620361
Title:
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
Authors:
Petrie, J R [et al]; REMOVAL Study Group inc. collaboration from:; Shore, Angela ( 0000-0003-3039-308x ) ; Miller, C.; Warren, Roderick
Abstract:
Metformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease.
Citation:
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. 2017 Lancet Diabetes Endocrinol
Publisher:
Elsevier
Journal:
Lancet: Diabetes & Endocrinology
Issue Date:
9-Jun-2017
URI:
http://hdl.handle.net/11287/620361
DOI:
10.1016/S2213-8587(17)30194-8
PubMed ID:
28615149
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S2213-8587(17)30194-8
Type:
Journal Article
Project details (details from EDGE):
EDGE Project ID: 10195
Language:
en
Description:
RD&E were one of the study sites for this project.
ISSN:
2213-8595
Appears in Collections:
Diabetes/Endocrine Services; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPetrie, J R [et al]en
dc.contributor.authorREMOVAL Study Group inc. collaboration from:en
dc.contributor.authorShore, Angelaen
dc.contributor.authorMiller, C.en
dc.contributor.authorWarren, Rodericken
dc.date.accessioned2017-07-14T09:20:48Z-
dc.date.available2017-07-14T09:20:48Z-
dc.date.issued2017-06-09-
dc.identifier.citationCardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. 2017 Lancet Diabetes Endocrinolen
dc.identifier.issn2213-8595-
dc.identifier.pmid28615149-
dc.identifier.doi10.1016/S2213-8587(17)30194-8-
dc.identifier.urihttp://hdl.handle.net/11287/620361-
dc.descriptionRD&E were one of the study sites for this project.en
dc.description.abstractMetformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S2213-8587(17)30194-8en
dc.rightsArchived with thanks to The lancet. Diabetes & endocrinologyen
dc.subjectWessex Classification Subject Headings::Endocrinology::Diabetesen
dc.titleCardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.en
dc.typeJournal Articleen
dc.identifier.journalLancet: Diabetes & Endocrinologyen
dc.description.fundingJuvenile Diabetes Research Foundation Internationalen
dc.type.versionIn press (epub ahead of print)en
dc.description.projectreferencenumberEDGE Project ID: 10195en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.